DE60334068D1 - VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN) - Google Patents
VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN)Info
- Publication number
- DE60334068D1 DE60334068D1 DE60334068T DE60334068T DE60334068D1 DE 60334068 D1 DE60334068 D1 DE 60334068D1 DE 60334068 T DE60334068 T DE 60334068T DE 60334068 T DE60334068 T DE 60334068T DE 60334068 D1 DE60334068 D1 DE 60334068D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- phenyl
- pyrrol
- isopropyl
- sup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20020413A CZ296967B6 (cs) | 2002-02-01 | 2002-02-01 | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| PCT/CZ2003/000007 WO2003068739A1 (en) | 2002-02-01 | 2003-01-30 | Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7- 3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60334068D1 true DE60334068D1 (de) | 2010-10-21 |
Family
ID=27674298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60334068T Expired - Lifetime DE60334068D1 (de) | 2002-02-01 | 2003-01-30 | VERFAHREN ZUR HERSTELLUNG EINER AMORPHEN FORM DES HEMICALCIUMSALZES VON (3R, 5R)-7-c3-PHENYL-4-PHENYL CARBAMOYL-2-(4-FLUORPHENYL)-5-ISOPROPYL PYRROL-1-YLÜ-3,5-DIHYDROXY HEPTAN SÄURE (ATORVASTATIN) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7208608B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1470106B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005521685A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040081172A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE480516T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003213986A1 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ296967B6 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60334068D1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA007432B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2347324T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0402590A3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL209756B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1470106E (cg-RX-API-DMAC7.html) |
| UA (1) | UA76826C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003068739A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2520740C (en) | 2003-04-11 | 2012-06-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
| WO2005005384A1 (en) * | 2003-07-15 | 2005-01-20 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
| CA2560252C (en) * | 2004-03-17 | 2009-08-04 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| WO2006008091A2 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
| EP1784389A4 (en) * | 2004-08-27 | 2009-03-25 | Biocon Ltd | PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM |
| KR20090033405A (ko) * | 2004-10-18 | 2009-04-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법 |
| WO2006048893A2 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | A process for synthesis of large particle size statin compounds |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
| CA2619486C (en) | 2005-08-15 | 2015-05-12 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
| AU2006281237A1 (en) | 2005-08-15 | 2007-02-22 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
| ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium |
| KR101050722B1 (ko) * | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
| WO2010069593A1 (en) * | 2008-12-19 | 2010-06-24 | Krka, D. D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| EP2327682A1 (en) * | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| CN103108863B (zh) * | 2010-04-19 | 2015-08-19 | 中化帝斯曼制药有限公司荷兰公司 | 低醚杂质的阿托伐他汀的制备 |
| CN108774164A (zh) * | 2018-05-29 | 2018-11-09 | 宣城美诺华药业有限公司 | 一种阿托伐他汀钙合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
| PT848704E (pt) * | 1995-07-17 | 2002-03-28 | Warner Lambert Co | Forma cristalina iii de um hemi-sal de calcio do acido ¬r-(r*,r*)|-2-(4-fluorofenil)-beta-delta-di-hidroxi-5-(1-metil-etil)-3-fenil-4-¬(fenilamino)carbonil|-1h-pirrole-1-heptanico(atorvastatina) |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| IN191236B (cg-RX-API-DMAC7.html) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| IN190564B (cg-RX-API-DMAC7.html) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
-
2002
- 2002-02-01 CZ CZ20020413A patent/CZ296967B6/cs not_active IP Right Cessation
-
2003
- 2003-01-30 ES ES03709588T patent/ES2347324T3/es not_active Expired - Lifetime
- 2003-01-30 WO PCT/CZ2003/000007 patent/WO2003068739A1/en not_active Ceased
- 2003-01-30 HU HU0402590A patent/HUP0402590A3/hu unknown
- 2003-01-30 PL PL370495A patent/PL209756B1/pl not_active IP Right Cessation
- 2003-01-30 US US10/502,632 patent/US7208608B2/en not_active Expired - Lifetime
- 2003-01-30 EP EP03709588A patent/EP1470106B1/en not_active Expired - Lifetime
- 2003-01-30 UA UA20040907211A patent/UA76826C2/uk unknown
- 2003-01-30 KR KR10-2004-7011960A patent/KR20040081172A/ko not_active Withdrawn
- 2003-01-30 PT PT03709588T patent/PT1470106E/pt unknown
- 2003-01-30 EA EA200400977A patent/EA007432B1/ru not_active IP Right Cessation
- 2003-01-30 AT AT03709588T patent/ATE480516T1/de not_active IP Right Cessation
- 2003-01-30 JP JP2003567871A patent/JP2005521685A/ja active Pending
- 2003-01-30 DE DE60334068T patent/DE60334068D1/de not_active Expired - Lifetime
- 2003-01-30 AU AU2003213986A patent/AU2003213986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040081172A (ko) | 2004-09-20 |
| UA76826C2 (uk) | 2006-09-15 |
| EA200400977A1 (ru) | 2004-12-30 |
| CZ296967B6 (cs) | 2006-08-16 |
| EP1470106A1 (en) | 2004-10-27 |
| ES2347324T3 (es) | 2010-10-28 |
| PL370495A1 (en) | 2005-05-30 |
| HUP0402590A3 (en) | 2010-06-28 |
| JP2005521685A (ja) | 2005-07-21 |
| ATE480516T1 (de) | 2010-09-15 |
| US20050131055A1 (en) | 2005-06-16 |
| US7208608B2 (en) | 2007-04-24 |
| CZ2002413A3 (cs) | 2003-10-15 |
| WO2003068739A1 (en) | 2003-08-21 |
| EA007432B1 (ru) | 2006-10-27 |
| PT1470106E (pt) | 2010-09-23 |
| PL209756B1 (pl) | 2011-10-31 |
| AU2003213986A1 (en) | 2003-09-04 |
| HUP0402590A2 (hu) | 2005-03-29 |
| EP1470106B1 (en) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE480516T1 (de) | Verfahren zur herstellung einer amorphen form des hemicalciumsalzes von (3r, 5r)-7-c3-phenyl-4- phenyl carbamoyl-2-(4-fluorphenyl)-5-isopropyl pyrrol-1-ylü-3,5-dihydroxy heptan säure (atorvastatin) | |
| DE60012045D1 (de) | Verfahren zur herstellung von amorphem atorvastatin | |
| ATE410413T1 (de) | Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol- heptansäureestern mit calciumhydroxid | |
| RU2003125647A (ru) | Способ синтеза авторвастатина и промежуточный фенилборонат (вараинты) | |
| JP2005521685A5 (cg-RX-API-DMAC7.html) | ||
| AU2002323570A1 (en) | Bicyclic compounds as inhibitors of chemokine binding to us28 | |
| DE59307409D1 (de) | Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester | |
| NO20023126L (no) | Fremgangsmåte for fremstilling av citalopram | |
| ATE521600T1 (de) | Verfahren zur herstellung von statinen | |
| CA1245226A (en) | METHOD FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATE COMPOUNDS | |
| EA200501734A1 (ru) | Способ получения (4-гидрокси-6-оксотетрагидропиран-2-ил)ацетонитрила и его производных | |
| US7361772B2 (en) | Process for the production of atorvastatin calcium | |
| ATE394393T1 (de) | Neue polymorphe formen eines 1-pyrrol-derivates, zwischenprodukt zur herstellung von atorvastatin | |
| EA200200641A1 (ru) | Кальцийдикарбоксилатные эфиры, способы их получения и лечение ими заболевания сосудов и диабета | |
| US7615647B2 (en) | Process for producing atorvastatin hemicalcium | |
| HUP9802936A2 (hu) | Eljárás sztatinok előállítására laktonképzéssel | |
| ATE478837T1 (de) | Verfahren zur herstellung von benzylaminderivaten | |
| DE602004020050D1 (de) | Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte | |
| ATE155134T1 (de) | Verfarhen zur herstellung von alpha-aryl-gamma- butyrolactonen | |
| CN104619684A (zh) | 生产阿托伐他汀中间体的方法 | |
| AU4414297A (en) | Method of preparing phosphodiesterase iv inhibitors | |
| WO2025184448A3 (en) | Methods and intermediates for preparing therapeutic compounds | |
| DE69815906D1 (de) | Verfahren zur Herstellung von Chloroacetylaminothiazoleaceticsäure Derivate | |
| WO2005033078A1 (en) | Process for the production of atorvastatin calcium | |
| ES2121685A1 (es) | Procedimiento para la obtencion de (+)-trans-4(4-fluorofenil)-3-hidroximetil-1-metil-piperidina. |